A long-term study to evaluate safety and efficacy of pregabalin in the treatment of postherpetic neuralgia.
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Pregabalin (Primary)
- Indications Postherpetic neuralgia
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Nov 2016 Results of a retrospective analysis from NCT00394901, NCT00553475, NCT00407745, NCT00424372, NCT00553280, NCT01202227 studies, published in the Clinical Drug Investigation
- 28 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2008 Patient number changed from 150 to 126 as reported by ClinicalTrials.gov.